Brazilian Health Regulatory Agency ANVISA has granted marketing approval to Zylox-Tonbridge Medical Technology’s ZENFlow Tiger LD PTA Dilatation Catheter (ZENFlow Tiger).
With this approval, the company intends to launch the product in the South American market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ZENFlow Tiger features a tapered tip and short shoulder that enables easier access through complex lesions thereby facilitating in protecting normal blood vessels.
Its coaxial catheter shaft design also allows for rapid inflation and deflation. It is available in various sizes for use in different clinical needs.
The low-temperature molding technology ensures non-compliance while the braided delivery shaft provides pushability and kink resistance.
The company also anticipates using ZENFlow Tiger in treating Budd-Chiari syndrome, iliac vein compression syndrome, and other peripheral vascular occlusions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also expects better treatment efficacy of the product, when properly used along with mechanical thrombectomy devices and peripheral stents.
This April, Zylox-Tonbridge formed a strategic alliance with Guangdong Hicicare Science to facilitate the commercialisation of vascular guidewire products, under a co-branded label in China.
The partnership’s aim is to bring new neuro and peripheral-vascular interventional devices to Chinese physicians and patients.
The company generated a revenue of 6.23m yuan ($0.85m), representing a YoY increase of 128.7% during the first half of this year.
